Showing 1 - 10 of 13
Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...
Persistent link: https://www.econbiz.de/10010300533
Dieser Beitrag diskutiert den Einfluss vergangener gesundheitspolitischer Reformgesetze in Deutschland auf Wahl- und …
Persistent link: https://www.econbiz.de/10010300558
Persistent link: https://www.econbiz.de/10001406395
Persistent link: https://www.econbiz.de/10011541102
Persistent link: https://www.econbiz.de/10010509297
Persistent link: https://www.econbiz.de/10001586927
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...
Persistent link: https://www.econbiz.de/10009522774
Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...
Persistent link: https://www.econbiz.de/10009492625
This paper discusses the influence of recent health care reform acts in Germany on choice, guidance and access from the perspective of patients, insured, insurers, and health care providers. Particular emphasis is put on health policy reforms since 2004, i.e. the Social Health Insurance...
Persistent link: https://www.econbiz.de/10009500545
Persistent link: https://www.econbiz.de/10004800142